GeekWire July 24, 2024
Taylor Soper

Oisín Biotechnologies, a Seattle-based startup focused on treating aging-related diseases, raised the first close of a $15 million Series A round.

  • The company is developing preclinical therapies to eliminate unwanted fat cells and build muscle mass to address frailty.
  • Oisín was founded in 2016...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
First Comprehensive Review of SMA Drugs Offers Long-Term Insights, Outcome Gaps
Drugmaker might be 1st healthcare company to top $1 trillion valuation
Pharma Pulse 9/5/24: Legal Advice for DSCSA Compliance Teams, Pharmacy Students Discuss Learning Through Social Media Platforms & more
RNA treatment shows promise for enhancing memory and reducing anxiety
57 Million Eligible For GLP-1 Drug Coverage In U.S. And That’s Just Those Under 65

Share This Article